Deucravacitinib
Deucravacitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against non-receptor tyrosine-protein kinase TYK2. In addition, it is known to target tyrosine-protein kinase JAK1 and bone morphogenetic protein receptor type-2.
Trade Name | |
---|---|
Common Name | Deucravacitinib |
Indication | |
Drug Class | Tyrosine kinase inhibitors: janus kinase inhibitors; deuterated compounds |